Abstract
In 1996 interferon (IFN)beta was the first biopharmaceutical product to be approved for the treatment of relapsing-remitting multiple sclerosis (MS). In 2006 the more potent monoclonal antibody natalizumab was approved. Presently, a number of monoclonal antibodies are being studied, including alemtuzumab, daclizumab and rituximab, which have all shown promising results. However, the monoclonal antibodies generally have a less favourable safety profile and are more expensive than the currently used first-line therapies, IFNb and glatiramer acetate.
| Bidragets oversatte titel | Biological treatment of multiple sclerosis |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 170 |
| Udgave nummer | 24 |
| Sider (fra-til) | 2156-9 |
| Antal sider | 4 |
| ISSN | 0041-5782 |
| Status | Udgivet - 9 jun. 2008 |
| Udgivet eksternt | Ja |
Emneord
- Alemtuzumab
- Antibodies, Monoclonal/therapeutic use
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal, Murine-Derived
- Antibodies, Neoplasm/therapeutic use
- Daclizumab
- Humans
- Immunoglobulin G/therapeutic use
- Immunoglobulins, Intravenous/therapeutic use
- Immunologic Factors/therapeutic use
- Immunosuppressive Agents/therapeutic use
- Interferon-beta/therapeutic use
- Multiple Sclerosis/drug therapy
- Natalizumab
- Rituximab